Microbiology Independent Research Journal (MIR Journal)

Advanced search

Dr. Julia Romanova

Scientific activities

1981-1995 Institute of Experimental Medicine, St. Petersburg, Russia

1989 Ph.D. Thesis defended (Virology)

Postdoctoral Training

1992 Royal Medical University, Newcastle, Australia

1994 Influenza Branch, Centers for Disease Control (CDC), Atlanta, Georgia, USA,

1995-2006 Institute of Applied Microbiology, University of Natural Resources and Life Sciences, Vienna, Austria

2006-2012 Green Hills Biotechnology AG, Vienna, Austria

2012 Habilitation Thesis defended (Virology)

2014-2015 HSC Development GmbH, Tulln, Austria

2016-2020 EURRUS GmbH, Tulln, Austria

Сurrent LLC Pharmenterprises, Moscow, Russia

Dr. Julia Romanova began her scientific carrier as a virologist in the St. Petersburg Institute for Experimental Medicine (Russia) where she was involved in the development of an attenuated live cold adapted influenza vaccine. After defending her PhD, Dr. Romanova worked at the Royal Medical University (Newcastle, Australia) and in the Centres for Disease control (CDC, USA). From 1995 to 2006 Dr. Romanova has been working at the Institute of Applied Microbiology (Vienna, Austria). In 2006 Dr. Romanova joined company Avir Green Hills Biotechnology AG for the development of a new generation of live replication-deficient intranasal influenza vaccine obtained by reverse genetics methods. This technology is based on the attenuation of influenza virus by deletion of the nonstructural NS1 gene from the genome of vaccine strains. Dr. Romanova was leading a department developing vaccine strains. Since this time, her main interest was the genetic determinants of influenza virus infectivity and immunogenicity of influenza vaccines. She found that an efficient intranasal vaccination with a live virus requires a certain level of stability of main surface glycoprotein hemagglutinin in order to achieve an optimal virus uptake by the nasal epithelial cells and induce a sufficient immune response. The pH of the hemagglutinin activation was found to be a major factor for the infectivity of highly pathogenic avian influenza viruses for mammals.

List of most relevant publications of Romanova J (Romejko-Gurko J)

  1. Alexandrova GI, Polezhaev FI, Budilovsky GN, Garmashova LM, Topuria NA, Egorov AY, Romejko-Gurko YR, Koval TA, Lisovskaya KV, Klimov AI, et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun. 1984 Jun;44(3):734-9.
  2. Romanova Yu, R., F. I. Polezhaev, M. A. Shneider, and G. I. Aleksandrova. 1986. Interfering activity of epidemic, attenuated and recombinant strains of influenza A virus. Acta Virol. 30:349-352
  3. Alexandrova, G. I., G. N. Budilovsky, T. A. Koval, F. I. Polezhaev, L. M. Garmashova, Z. Ghendon Yu, Y. R. Romanova, and A. A. Smorodintsev. 1986. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine. 4:114-118
  4. Romanova IuR, Egorov AIu, Lisovskaia KV, Medvedeva TE, Nevedomskaia GN, Aleksandrova GI, Klimov AI. The effect of amplifying reproduction of influenza virus in mouse lungs during simultaneous infection with two cold-adapted strains. Vopr Virusol. 1989 Sep-Oct;34(5):547-53 (Russian)
  5. Rudenko, L. G., A. Ramirez, M. Barro, M. I. Gushchina, R. E. Armanda, T. A. Ermachenko, R. Romanova Iu, E. P. Grigor'eva, G. I. Aleksandrova, and N. I. Lonskaia. 1991. The inoculation properties of live recombinant influenza vaccine types A and B used separately and jointly in children 3 to 14. Vopr Virusol. 36:472-474 (Russian)
  6. Medvedeva, T. E., Iu. R. Romanova, M. I. Gushchina, L. G. Rudenko, Z. Gendon Iu, G. I. Aleksandrova, and A. I. Klimov. 1990.The ts phenotype of reisolates from children inoculated with live cold- adapted influenza vaccine type A. Vopr Virusol. 35:101-105 (Russian)
  7. Romanova IuR, Aleksandrova GI. Interference and its overcoming during the reproduction of 2 influenza A virus strains in an experiment. Vopr Virusol. 1993 Jul-Aug;38(4):149-52 (Russian)
  8. Romanova Iu, R., and G. I. Aleksandrova. 1993.Interference and its overcoming during the reproduction of 2 influenza A virus strains in an experiment. Vopr Virusol. 38:149-152 (Russian)
  9. Romanova, J. R., T. A. Ermachenko, G. I. Alexandrova, and G. A. Tannock. 1994. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine. 12:23-27
  10. Tannock, G. A., J. R. Romanova, and J. A. Paul. 1995. The immunogenicity of reassortants of the cold-adapted influenza A master strain A/Ann Arbor/6/60 is determined by both the genes for cold- adaptation and the haemagglutinin gene. Arch Virol. 140:201-209
  11. Romanova, J. R., G. A. Tannock, and G. I. Alexandrova. 1997. Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses. Vaccine. 15:653-658
  12. Klimov, A. I., J. R. Romanova, A. Y. Egorov, I. V. Lukashok, I. V. Kiseleva, G. I. Alexandrova, and N. J. Cox. 1995. Nucleotide sequences of the neuraminidase genes of influenza A/Leningrad/134/57 (H2N2) virus and two of its live, attenuated, cold- adapted variants. Virus Genes. 10:95-98
  13. Ferko, B., D. Katinger, A. Grassauer, A. Egorov, J. Romanova, B. Niebler, H. Katinger, and T. Muster. 1998. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis. 178:1359-1368
  14. Egorov, A., S. Brandt, S. Sereinig, J. Romanova, B. Ferko, D. Katinger, A. Grassauer, G. Alexandrova, H. Katinger, and T. Muster. 1998. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol. 72:6437-6441
  15. Grassauer, A., A. Y. Egorov, B. Ferko, I. Romanova, H. Katinger, and T. Muster. 1998. A host restriction-based selection system for influenza haemagglutinin transfectant viruses. J. Gen Virol. 79:1405-1409
  16. Ferko B, Stasakova J, Sereinig S, Romanova J, Katinger D, Niebler B, Katinger H, Egorov A. Hyperattenuated recombinant influenza A virus nonstructural – protein - encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol. 2001 Oct;75(19):8899-908.
  17. Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, Bovin N, Lim W, Katinger H, Egorov A. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology. 2003 Mar 1;307(1):90-7.
  18. Mochalova L, Gambaryan A, Romanova J, Tuzikov A, Chinarev A, Katinger D, Katinger H, Egorov A, Bovin N. Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology. 2003 Sep 1;313(2):473-80.
  19. Katinger D, Romanova J, Ferko B, Fekete H, Egorov A. Effect of a single mutation in neuraminidase on the properties of Influenza B virus isolates. Arch Virol. 2004 Jan;149(1):173-81. Epub 2003 Sep 22.
  20. Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, Wolkerstorfer A, Katinger H, Egorov A. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology. 2004 Jun 20;324(1):67-73.
  21. Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res. 2004 Jul;103(1-2):187-93.
  22. Katinger D, Mochalova L, Chinarev A, Bovin N, Romanova J. Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates. Arch Virol. 2004 Jun 30
  23. Stasakova J, Ferko B, Kittel C, Sereinig S, Romanova J, Katinger H, Egorov A. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol. 2005 Jan;86(Pt 1):185-95.
  24. Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A. Related Articles, Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.J Virol. 2005 Aug;79(16):10672-7.
  25. E.M.Rapoport, L.V.Mochalova, H.-J.Gabius, J.Romanova, N.V.Bovin Pattering of Lectins of Vero and MDCK Cells and influenza viruses: the search for additional virus/cell interactions. Handbook of Carbohydrate engineering. Edited by Kevin J.Yarema. Taylor&Francis.2005
  26. E.M.Rapoport, L.V.Mochalova, H.-J.Gabius, J.Romanova, N.V.Bovin Search for additional. influenza virus to cell interactions. Glycoconj.J (2006) 23: 115-125
  27. Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, Vinogradova TI, Katinger H, Kiselev OI, Egorov A. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb). 2006 May-Jul; 86(3-4):236-46.
  28. Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, Vinogradova T, Katinger H, Kiselev O, Egorov A. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol. 2006 Aug;13(8):898-904.
  29. Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol. 2006 Dec;80(23):11621-7.
  30. Fischlechner M, Reibetanz U, Zaulig M, Enderlein D, Romanova J, Leporatti S, Moya S, Donath E 2007,Fusion of enveloped virus nanoparticles with polyelectrolyte-supported lipid membranes for the design of bio/nonbio interfaces. Nano Lett. 2007 Nov;7(11):3540-6.
  31. Wressnigg N, Voss D, Wolff T, Romanova J, Ruthsatz T, Mayerhofer I, Reiter M, Nakowitsch S, Humer J, Morokutti A, Muster T, Egorov A, Kittel C. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine. 2009 May 11;27(21):2851-7
  32. Romanova J. The fight against new types of influenza virus. Biotechnol J. 2006 Dec;1(12):1381-92. Review
  33. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.PLoS One. 2009 Jun 19;4(6):e5984
  34. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T. A novel type of influenza vaccine: safety and immunogenicity of replication- deficient influenza virus created by deletion of the interferon antagonist NS1.J Infect Dis. 2010 Feb 1;201 (3):354-62.
  35. Krenn BM, Egorov A, Romanovskaya-Romanko E, Wolschek M, Nakowitsch S, Ruthsatz T, Kiefmann B, Morokutti A, Humer J, Geiler J, Cinatl J, Michaelis M, Wressnigg N, Sturlan S, Ferko B, Batishchev OV, Indenbom AV, Zhu R, Kastner M, Hinterdorfer P, Kiselev O, Muster T, Romanova J. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One. 2011 Apr 7;6(4):e18577.
  36. Nakowitsch S, Wolschek M, Morokutti A, Ruthsatz T, Krenn BM, Ferko B, Ferstl N, Triendl A, Muster T, Egorov A, Romanova J. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.Vaccine. 2011 Apr 27;29(19):3517-24
  37. Roethl E, Gassner M, Krenn BM, Romanovskaya-Romanko EA, Seper H, Romanova J, Nakowitsch S, Sturlan S, Wolschek M, Sirotkin A, Kiselev O, Muster T, Egorov A. Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. 2011 J Virol. 2011, 85, 21.
  38. Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines. Biotechnol J. 2014 Mar;9(3):405-14
  39. Morokutti A, Rediberger-Fritz M, Nakowitsch S, Krenn BM, Wressnigg N, Jungbauer A, Romanova J, Muster T, Popow-Kraupp T, Ferko B. Validation of the modified hemagglutination assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response. 2013 J clin Virol. 56(4) 323-30
  40. Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA. Inactivated and adjuvanted whole virion clade 2.2 H5N1 (A/chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol. 2013 Aug;20(8):1314-9
  41. Sergeeva MV, Kuznetsov VV, Kas'ianenko MA, Shaldzhian AA, Repko IA, Potapchuk MV, Romanova IuR, Tsybalova LM. Immunization with live attenuated A/H5N1 vaccine protects guinea pigs from reinfection. 2013 Vopr Virusol. Nov-Dec;58(6):36-9. (Russian)
  42. Sergeeva MV, Romanova IuR Vaccines against highly pathogenic influenza viruses of the avian origin Vopr Virusol. 2013 Jul-Aug; 58(4):4-9. Review. (Russian).
  43. Kittel C, Wressnigg N, Shurygina AP, Wolschek M, Stukova M, Romanovskaya-Romanko E,Romanova J, Kiselev O, Muster T, Egorov A. A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice. Arch Virol. 2015 Oct;160(10):2525-34
  44. Renner A, Romanova J, Ferko B, Schmutz H, Nebolsin V, Müller M, Badorrek P, Marth K, Pohl W. Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands. Pulmonary pharmacology & therapeutics. 2019, 59, 101852
  45. Ferko B, Romanova J, Rydlovskaya AV, Kromova TA, Proskurina OV, Amelina AN, Schmutz H, Renner A, Nebolsin VE. A novel oral glutarimide derivative XC8 suppresses Sephadex-induced lung inflammation in rats and ovalbumin-induced acute and chronic asthma in Guinea pigs. Current pharmaceutical biotechnology. 2019,20 (2), 146-156.
  46. Romanova J, Chikina E, Rydlovskaya A, Pohl W, Renner A, Zeifman A, Chuchalin A, Nebolsin V. New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial. 2020. Pulmonary therapy 6 (2), 351-369.